Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis.

Alimentary pharmacology & therapeutics - 1 Jun 2020

Carlsson Björn, Lindén Daniel, Brolén Gabriella, Liljeblad Mathias, Bjursell Mikael, Romeo Stefano, Loomba Rohit

Abstract excerpt

BACKGROUND: Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD) characterised by liver fat accumulation, inflammation and progressive fibrosis. Emerging data indicate that genetic susceptibility increases risks of NAFLD, NASH and NASH-related cirrhosis. AIMS: To review NASH genetics and discuss the potential for precision medicine approaches to treatment. METHOD:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Carcinoma, Hepatocellular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Genetic Testing

Share to Liver Neoplasms

Share to Non-alcoholic Fatty Liver Disease

Share to Precision Medicine

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 32383295
DOI: 10.1111/apt.15738
PMCID: PMC7318322

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis.PMID 32383295Read ↗

Genetics of nonalcoholic fatty liver disease.Semantic proximity Read ↗

Advances in the genetics of nonalcoholic fatty liver disease.Semantic proximity Read ↗

Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease.Semantic proximity Read ↗

Update on NAFLD genetics: From new variants to the clinic.Semantic proximity Read ↗

Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease.Semantic proximity Read ↗

Genetics and epigenetics of NAFLD and NASH: Clinical impact.Semantic proximity Read ↗

Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and TherapeuticsSemantic proximity Read ↗

Human genetics of metabolic dysfunction–associated steatotic liver disease: from variants to cause to precision treatmentSemantic proximity Read ↗

Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications.Semantic proximity Read ↗

PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date.Semantic proximity Read ↗

Genetics of Nonalcoholic Fatty Liver Disease: From Pathogenesis to TherapeuticsSemantic proximity Read ↗

PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.